Evidence map›Paper›PMID 35350193›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant.

Guilherme R F Campos, Nathalie Bonatti Franco Almeida, Priscilla Soares Filgueiras, Camila Amormino Corsini, Sarah Vieira Contin Gomes, Daniel Alvim Pena de Miranda, Jéssica Vieira de Assis, Thaís Bárbara de Souza Silva, Pedro Augusto Alves, Gabriel da Rocha Fernandes and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Guilherme R F CamposLaboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São Paulo State, Brazil.
Nathalie Bonatti Franco AlmeidaDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Priscilla Soares FilgueirasDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Camila Amormino CorsiniDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Sarah Vieira Contin GomesDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Daniel Alvim Pena de MirandaDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Jéssica Vieira de AssisDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Thaís Bárbara de Souza SilvaLaboratório de Imunologia de Doenças Virais, Instituto Rene Rachou - Fundação Oswaldo Cruz.
Pedro Augusto AlvesLaboratório de Imunologia de Doenças Virais, Instituto Rene Rachou - Fundação Oswaldo Cruz.
Gabriel da Rocha FernandesDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Jaquelline Germano de OliveiraLaboratório de Imunologia Celular e Molecular, instituto Rene Rachou - Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
Paula RahalLaboratório de Estudos Genômicos, Departamento de Biologia, Instituto de Biociências Letras e Ciências Exatas (IBILCE), Universidade Estadual Paulista (Unesp), São José do Rio Preto, Brazil.
Rafaella Fortini Grenfelle QueirozDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Maurício L NogueiraLaboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São Paulo State, Brazil; Hospital de Base, São José do Rio Preto, São Paulo State, Brazil; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Fundação Oswaldo Cruz · BRFaculdade de Medicina de São José do Rio Preto · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics II (CREATE-NEO II)U01AI151807 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Kathryn Alyce Hanley, MAURICIO Lacerda NOGUEIRA · 2020 to 2026
$9.8M
NIAID NIH HHS U01 AI151807
6 · The paper itself

Abstract

The emergence of the new SARS-CoV-2 Omicron variant, which is known to accumulate a huge number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. In this scenario, we evaluated the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. The percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 17% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times, indicating a positive impact of this vaccine combination in the serological immune response.

Identifiers

PMID35350193
PMCPMC8963699
OpenAlexW4220919685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.